Target intelligence / Profile preview

Carbonyl reductase [NADPH] 1 (CBR1)

Target
CBR1
Molecular classification
Enzyme, Oxidoreductase, Short-chain dehydrogenase/reductase
01

Overview

Carbonyl reductase [NADPH] 1 (CBR1) is a cytosolic, monomeric NADPH-dependent oxidoreductase belonging to the short-chain dehydrogenase/reductase (SDR) superfamily. It is widely distributed in human tissues, with high expression in the liver, epidermis, and gastrointestinal tract, where it plays a critical role in the metabolism of a broad range of endogenous and xenobiotic carbonyl compounds, including quinones, prostaglandins, and lipid aldehydes. CBR1 is highly clinically relevant due to its role in metabolizing anthracycline chemotherapeutics, such as doxorubicin and daunorubicin, into their corresponding secondary alcohol metabolites (e.g., doxorubicinol), which are less effective as anticancer agents and significantly contribute to chronic cardiotoxicity. Consequently, CBR1 is a major therapeutic target for co-administration strategies; inhibiting CBR1 can prevent the formation of cardiotoxic metabolites, thereby mitigating anthracycline-induced cardiotoxicity and overcoming drug resistance in various cancers. Additionally, CBR1 plays a protective role against oxidative stress by detoxifying reactive lipid aldehydes, meaning its inhibition must be carefully managed to avoid cellular damage.

Other names
Carbonyl reductase 1CBR1CBRCRNSDR21C115-hydroxyprostaglandin dehydrogenase [NADP(+)]Alcohol dehydrogenase [NAD(P)+] CBR1NADPH-dependent carbonyl reductase 1Prostaglandin 9-ketoreductasePG-9-KR
02

Mechanism of action

Inhibition of carbonyl reductase [NADPH] 1 prevents the reduction of anthracyclines (such as doxorubicin and daunorubicin) to their cardiotoxic alcohol metabolites (doxorubicinol and daunorubicinol), thereby reducing cardiotoxicity and enhancing chemotherapeutic efficacy.

03

Biological functions

MetabolismOxidative stress responseApoptosis regulationProstaglandin metabolismXenobiotic detoxification
04

Disease associations

CancerCardiovascular diseaseNeurodegenerative diseaseInflammation
05

Safety considerations

Potential accumulation of reactive carbonylsImpaired prostaglandin metabolismAlteration of xenobiotic clearanceIncreased risk of oxidative stress-induced cellular damage
06

Interacting drugs

10 more in the full profile.

07

Biomarkers

CBR1 expression levelCBR1 genetic polymorphismsDoxorubicinol levelsDaunorubicinol levels

Beyond the preview

Go deeper on Carbonyl reductase [NADPH] 1 (CBR1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Carbonyl reductase [NADPH] 1 (CBR1).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call